Watson Pharmaceuticals Inc. (WPI) said Pfizer Inc. (PFE) is suing Watson to prevent the generic drug maker from selling a knock-off version of Viagra.
The company said Thursday it has applied for regulatory approval to sell its sildenafil citrate tablets, a generic version of Pfizer's erectile-dysfunction treatment.
But it said Pfizer filed suit Wednesday to prevent Watson's commercializing the competitor prior to a patent expiration.
A Pfizer representative wasn't able to comment immediately on the matter.
Viagra accounted for $1.93 billion in sales for Pfizer last year, representing about 2.8% of total revenue.
Watson shares were up 0.2% at $64.04 after hours while Pfizer's were up 1 cent at $21.01.
Comments
last commentWhy does Watson think they're gonna get a bye on the patent restriction one microsecond before it expires? I could see it if Viagra were a sovereign cure for every STD known to man, or some other highly desirable cure where Pfizer could be demonized for not providing it gratis, but not Viagra.
Log in to vote
you must be a PFE shareholder lol
Log in to vote
It's possible; I have a fair few dollars in pharmaceutical mutual funds, and I don't keep track of each and every share. Probably have some Watson though, too. :) I'm just irritated by this type of thing.
Log in to vote
Actually, what was applied for was approval of the drug. Their patent expires March 27, 2012 and Watson wants to have their drug already approved and ready to ship. No sense waiting until later to dick around with the approval process.
Here are the details on the Viagra patent:
accessrx.com
Log in to vote
There is an whole other patent that Pfizer is trying to enforce in order to block any generics until 2019. This is currently under debate and lawsuits.
bloomberg.com
Log in to vote
Oh well, that's a different story then. Pfuck Pfizer, in that case.
Log in to vote